Compare AGMH & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGMH | SCYX |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 32.6M |
| IPO Year | 2017 | 2014 |
| Metric | AGMH | SCYX |
|---|---|---|
| Price | $1.21 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 30.6K | ★ 318.1K |
| Earning Date | 10-10-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $257,000.00 |
| Revenue This Year | N/A | $90.24 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.57 |
| 52 Week High | $18.10 | $1.29 |
| Indicator | AGMH | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 35.89 | 61.59 |
| Support Level | $0.06 | $0.68 |
| Resistance Level | $2.46 | $1.29 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 20.00 | 73.68 |
AGM Group Holdings Inc is an integrated technology company. The company focuses on blockchain-oriented ASIC chip design, high-end crypto miner production, and fintech technology software services. The company generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.